
The EMA has awarded EU marketing authorisation to GlaxoSmithKline and Innovia’s single inhaler triple therapy Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for …

The good news keeps on rolling in for GSK, with the FDA approval for its triple therapy inhaler.
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion

